Shardul Amarchand Mangaldas & Co. Advises On IPO Of Emcure Pharmaceuticals

Shardul Amarchand Mangaldas & Co. advised Emcure Pharmaceuticals Limited (“Issuer”) on the IPO of 19,375,070 equity shares aggregating to ₹19,520.27 million (approximately USD 234 million), comprising a fresh issue of 7,946,231 equity shares aggregating to ₹8000 million and offer for sale by certain shareholders of 11,428,839 equity shares aggregating to ₹11,520.27 million (the “Offer”). 

The Issue had an overall subscription of 68.50x, with the retail individual portion oversubscribed 7.49x; QIB portion oversubscribed 190.88x, non-institutional bidders (more than 0.20 million – up to 1.00 million) oversubscribed 39.05x and non-institutional bidders (above 1.00 million) oversubscribed 55.39x.

Emcure Pharmaceuticals Limited is a prominent pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. 

The transaction team comprised Nikhil Naredi - Partner; Priya Awasthi - Partner; Rakshita Poddar- Associate and Manish Soni - Associate.